CXCL13 as a Biomarker of Complex Common Variable Immunodeficiency.

Area of Science:

• Immunology
• Biomarker Discovery

Background:

• Common Variable Immunodeficiency (CVID) is characterized by impaired antibody production and recurrent infections.
• Prognostic biomarkers for CVID are currently limited.
• CXCL13, a regulator of germinal center responses and T follicular helper (Tfh) cells, is implicated in B cell activity and elevated in inflammatory conditions.

Purpose of the Study:

• To investigate alterations in serum CXCL13 levels in CVID patients.
• To determine if serum CXCL13 can stratify CVID patients based on clinical and immune phenotypes.

Main Methods:

• Comparison of serum CXCL13 levels between CVID patients and healthy donors (HD).
• Association of CXCL13 levels with clinical complications and immune cell phenotypes in CVID.

Main Results:

• Serum CXCL13 levels were significantly higher in CVID patients compared to HD, especially in females.
• Elevated CXCL13 correlated positively with clinical complications and circulating Tfh cells (cTfh) in CVID.
• Higher CXCL13 levels were linked to increased clinical complications, CD21^low B cells, or decreased switched memory B cells.

Conclusions:

• CXCL13 serves as a valuable biomarker for categorizing heterogeneous CVID patients.
• Serum CXCL13 can help identify complex disease phenotypes within CVID.